IceCure Doubles Down on U.S. Expansion Amid 70% Cryoablation System Growth
Event summary
- IceCure Medical expanded its U.S. sales and marketing teams to meet surging demand for ProSense® cryoablation systems.
- The company added dedicated professionals in key territories including New York, Southern California, and the Midwest.
- Active U.S. commercial install base of ProSense® grew 70% following FDA marketing authorization in October 2025.
- Procedures are now being performed in major metropolitan areas across the U.S., including Los Angeles, New York, and Atlanta.
The big picture
IceCure's expansion comes as the company capitalizes on growing physician demand and supportive clinical guidelines following FDA authorization. The move reflects broader industry trends toward minimally invasive tumor removal options, positioning IceCure to capture market share in key oncology segments.
What we're watching
- Market Penetration
- The pace at which IceCure can expand its geographic footprint and clinical adoption in the U.S.
- Regulatory Dynamics
- Whether supportive clinical guidelines will continue to drive demand for ProSense® cryoablation systems
- Execution Risk
- How effectively IceCure can scale its commercial team to meet surging demand and maintain growth momentum
Related topics